Cochlear Limited
ASX: COH
New product launches and expanding referral networks drive Cochlear’s steady revenue growth.
(Source: TradingView) 3-Month Performance Profile of COH on a DTF compared to S&P/ASX 200 (XJO).
Cochlear reported FY25 sales revenue of $2,355.8 million, up 4% year-on-year, supported by steady unit growth and key product launches, including the Nucleus Nexa Implan
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
